Patents Assigned to Wyeth
  • Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport
    Patent number: 6750364
    Abstract: This invention provides compounds of the formula: wherein X is (CH2)n, O, S, SO, SO2 or CR1R2; n is 1 or 2; R1 and R2 are H, halogen, hydroxy, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or R1 and R2, taken together form cycloalkyl of 3 to 6 carbon atoms, an alkylidene of up to 6 carbon atoms or a carbonyl; R3, R4 and R5 are H or alkyl of 1 to 6 carbon atoms; Z is H, alkyl of 1 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms or alkoxycarbonyl of 2 to 7 carbon atoms; or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods for their use in treating or preventing characterized by glutamate hypofunction, including schizophrenia, schizoaffective disorder and schizophreniform disorder, and for the treatment of cognitive deficits due to aging, stroke, Alzheimer's disease or other neurodegenerative diseases.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: June 15, 2004
    Assignee: Wyeth
    Inventors: Gary Paul Stack, John Dunlop, Alexander Alexei Greenfield, Jonathan Laird Gross
  • 2-Phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
    Publication number: 20040110824
    Abstract: The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: 1
    Type: Application
    Filed: November 24, 2003
    Publication date: June 10, 2004
    Applicant: Wyeth
    Inventors: Chris P. Miller, Michael D. Collini, Bach D. Tran, Arthur A. Santilli
  • Methods for diagnosing RCC and other solid tumors
    Publication number: 20040110221
    Abstract: Methods, systems and equipment for diagnosing renal cell carcinoma (RCC) and other solid tumors. This invention identifies numerous disease genes that are differentially expressed in the peripheral blood of patients having RCC or other solid tumors relative to disease-free humans. These disease genes can be used as surrogate markers for detecting the presence or absence of RCC or other solid tumors.
    Type: Application
    Filed: November 21, 2003
    Publication date: June 10, 2004
    Applicant: Wyeth
    Inventors: Natalie C. Twine, Michael E. Burczynski, William L. Trepicchio, Andrew J. Dorner, Jennifer A. Stover, Donna K. Slonim
  • Tricyclic protein kinase inhibitors
    Publication number: 20040110762
    Abstract: This invention provides compounds of formula 1, having the structure 1
    Type: Application
    Filed: July 10, 2003
    Publication date: June 10, 2004
    Applicant: WYETH
    Inventors: Dan M. Berger, Minu D. Dutia, Frenel F. DeMorin, Diane H. Boschelli, Dennis W. Powell, Hwei-Ru Tsou, Allan Wissner, Nan Zhang, Fei Ye, Biqi Wu
  • Treatments using venlafaxine
    Publication number: 20040110829
    Abstract: This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: 1
    Type: Application
    Filed: November 25, 2003
    Publication date: June 10, 2004
    Applicant: Wyeth
    Inventors: Richard L. Rudolph, Albert T. Derivan
  • Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia
    Publication number: 20040110780
    Abstract: This invention provides compounds of Formula I having the structure: 1
    Type: Application
    Filed: September 4, 2003
    Publication date: June 10, 2004
    Applicant: Wyeth
    Inventor: Baihua Hu
  • 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
    Publication number: 20040110823
    Abstract: The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: 1
    Type: Application
    Filed: July 10, 2003
    Publication date: June 10, 2004
    Applicant: Wyeth
    Inventors: Chris P. Miller, Michael D. Collini, Bach D. Tran, Arthur A. Santilli
  • Piperazinyl-isatins
    Patent number: 6743796
    Abstract: This invention provides compounds of formula VI wherein Y is hydrogen, methyl, methoxy, methylthio or trifluoromethyl; R is hydrogen, C1-3alkyl or (CH2)nAr; n is 0, 1 or 2; and Ar is phenyl or methoxyphenyl, or a pharmaceutically acceptable salt thereof. These compounds are selective dopamine autoreceptor agonists useful in treating disease states involving hyperactivity of dopamine systems. The invention also comprises intermediate compounds, compositions and methods related to the compounds of formula VI.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: June 1, 2004
    Assignee: Wyeth
    Inventors: Lynne P. Greenblatt, Ivo Jirkovsky, Richard E. Mewshaw
  • N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
    Patent number: 6743787
    Abstract: This invention provides compounds of Formula I having the structure wherein R1, R2, R3, R4, W, X, and Y are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: June 1, 2004
    Assignee: Wyeth
    Inventors: Fuk-Wah Sum, Michael Sotirios Malamas
  • Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
    Publication number: 20040102480
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: November 21, 2002
    Publication date: May 27, 2004
    Applicant: Wyeth
    Inventors: Michael S. Malamas, Jay E. Wrobel, Arlene J. Dietrich, Zenan Li, Iwan Gunawan
  • 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
    Patent number: 6740675
    Abstract: The invention relates to compounds of Formula (I), to processes for their preparation and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: May 25, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph William Epstein, Semiramis Ayral-Kaloustian
  • Compositions, organisms and methodologies employing a novel human kinase
    Publication number: 20040096890
    Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, NRHK1. The novel protein kinase is encoded by a human gene comprising 21 exons. The human gene is localized in or near the 9q34 locus of human chromosome 9. The sequence similarity between the novel human protein and the consensus sequence of NIMA-related kinase indicates that the novel human protein may function as an NIMA-related kinase.
    Type: Application
    Filed: October 10, 2003
    Publication date: May 20, 2004
    Applicant: Wyeth
    Inventors: Wei Liu, Leeying Wu
  • Method of treating cardiovascular disease
    Publication number: 20040097538
    Abstract: This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 20, 2004
    Applicant: Wyeth
    Inventors: Neal I. Azrolan, Surendra N. Sehgal, Uma Sehgal, Steven J. Adelman
  • Compositions, organisms and methodologies employing a novel human kinase
    Publication number: 20040096889
    Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, HPK3P23. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.
    Type: Application
    Filed: October 10, 2003
    Publication date: May 20, 2004
    Applicant: Wyeth
    Inventors: Wei Liu, Leeying Wu
  • 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20040092564
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: October 28, 2003
    Publication date: May 13, 2004
    Applicant: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • Compositions, organisms and methodologies employing a novel human protein phosphatase
    Publication number: 20040091926
    Abstract: This invention provides compositions, organisms and methodologies employing a novel human gene encoding a protein that has sequence homology to a consensus sequence of calcineurin-like phosphoesterase family are disclosed. The novel protein is encoded by a human gene comprising 4 exons. The human gene is localized in the 10p15 locus of human chromosome 10. The sequence similarities between the novel human protein and the consensus sequence of calcineurin-like phosphoesterases indicate that the novel human protein may function as a calcineurin-like protein phosphatase.
    Type: Application
    Filed: October 24, 2003
    Publication date: May 13, 2004
    Applicant: Wyeth
    Inventors: Wei Liu, Leeying Wu, Roger Ford, Xiaobing Be
  • Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
    Publication number: 20040092457
    Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure 1
    Type: Application
    Filed: October 24, 2003
    Publication date: May 13, 2004
    Applicant: Wyeth
    Inventor: Scott C. Mayer
  • Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
    Publication number: 20040092526
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: October 23, 2003
    Publication date: May 13, 2004
    Applicant: Wyeth
    Inventors: Ping Zhou, Derek Cecil Cole, Michael Gerard Kelly, William Joseph Lennox
  • Combination therapy for type II diabetes or Syndrome X
    Patent number: 6734197
    Abstract: This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: May 11, 2004
    Assignee: Wyeth
    Inventors: Bruce Paul Randazzo, Philippe John Robert Vitou, John Thomas Gwynne
  • Fast dissolving tablet
    Patent number: 6733781
    Abstract: The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants which may cause a gritty or chalky sensation in the mouth. Convenient and economically feasible processes by which the tablets of the invention may be produced are also provided.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: May 11, 2004
    Assignee: Wyeth
    Inventors: Khawla A. Abu-Izza, Vincent H. Li, Jee L. Look, Graham D. Parr, Matthew K. Schineller